Blood Pressure Medication Recall, What the FDA Announcement Means for Patients

Quick Answer

The FDA has issued multiple recalls for blood pressure medications between 2022 and 2025 due to contamination risks, including nitrosamine impurities (potential carcinogens), undeclared ingredients, and metal contamination. For patients, these recalls mean checking prescription labels against FDA recall lists, consulting their healthcare provider before stopping any medication, and understanding that most recalls involve specific lots rather than entire drug categories.

Do not discontinue blood pressure medication without medical guidance, as untreated hypertension poses immediate health risks.

Key Facts

• In 2025, Teva Pharmaceuticals recalled over 580,000 capsules of prazosin hydrochloride due to elevated nitrosamine levels, a potentially carcinogenic contamination.
• The 2025 prazosin recall affected 1 mg, 2 mg, and 5 mg doses distributed by Teva Pharmaceuticals, plus 5 mg doses from Amerisource Health.
• Approximately 510,000 patients were prescribed prazosin at the time of the recall.
• In 2024, Unique Pharmaceutical Laboratories recalled 675 bottles of 20 mg Enalapril Maleate Tablets after failed impurity tests, classified as a Class II recall (potential temporary health risk).
• Glenmark Pharmaceuticals recalled over 11,100 bottles of bisoprolol fumarate and hydrochlorothiazide tablets (brand name Ziac) due to possible contamination.
• The FDA recalled certain bottles of spironolactone tablets due to possible aluminum contamination.
• Pfizer voluntarily recalled Accuretic (quinapril hydrochloride plus hydrochlorothiazide) in 2022.
• The FDA also issued warnings about Metoprolol Succinate ER not dissolving properly, affecting over 112,000 bottles.
• A separate recall involved products labeled as "Green" that contained undeclared tadalafil, detected during FDA testing in August 2025.

Background and Context

Blood pressure medications are among the most prescribed drug classes in the United States, with millions of patients relying on them daily to manage hypertension—a condition that increases the risk of heart attack, stroke, kidney disease, and other serious health problems. Recalls of these medications, therefore, have significant public health implications.

The term "recall" refers to a manufacturer's or FDA's action to remove a drug from the market when it is found to be defective, contaminated, or potentially harmful. Recalls are classified by the FDA into three classes based on the severity of potential health consequences.

Class I recalls involve situations where there is a reasonable probability that product use will cause serious adverse health consequences or death. Class II recalls involve products that might cause temporary or medically reversible health problems, or where the probability of serious harm is remote.

Class III recalls involve products that are unlikely to cause adverse health consequences but violate FDA regulations. The recalls covered in this analysis span multiple years and involve different contamination issues.

The most common concern has been nitrosamine impurities, which are chemical compounds that can form during drug manufacturing and have been classified as probable human carcinogens by the International Agency for Research on Cancer. The presence of nitrosamines in blood pressure medications—particularly in angiotensin II receptor blockers (ARBs) and now in prazosin—has triggered widespread recalls across the pharmaceutical industry.

Another contamination issue involves undeclared active ingredients. In August 2025, FDA testing detected tadalafil—a prescription drug used for erectile dysfunction—in products labeled as "Green." This is a serious safety concern because patients may unknowingly ingest a drug they neither need nor are medically cleared to take, potentially causing dangerous interactions with other medications they are using.

Metal contamination, such as aluminum found in spironolactone tablets, is also a recurring issue. While aluminum is commonly found in the environment, pharmaceutical products must meet strict purity standards to ensure that metal levels do not exceed safe thresholds.

Chronic exposure to elevated aluminum levels has been linked to neurological and bone health concerns, though the immediate risk from short-term exposure is generally low. The question of why these recalls keep happening relates to manufacturing processes, quality control failures, and the complexity of global supply chains.

Many generic drugs are produced in facilities outside the United States, where regulatory oversight may vary. The U.S.

FDA does inspect foreign manufacturing sites, but resource constraints mean that not every batch is tested before reaching patients. When contamination is discovered—often through routine testing by the manufacturer or FDA surveillance—recalls are initiated to remove affected lots from the market.

Detailed Explanation

How Recalls Are Initiated and Communicated

The recall process typically begins when a manufacturer discovers a quality issue during internal testing, or when the FDA detects a problem during routine inspections or product testing. In some cases, reports from healthcare providers or patients about adverse reactions may trigger an investigation that leads to a recall.

Once a problem is confirmed, the manufacturer works with the FDA to determine the scope of the recall—which lots are affected, how many units were distributed, and what patient populations may have been exposed. The FDA then classifies the recall (Class I, II, or III) and posts the information on its website along with press releases and safety alerts.

Patients are usually notified through multiple channels: media reports, healthcare provider communications, pharmacy notifications, and direct mail if the manufacturer has contact information. However, because many patients do not register their medications with manufacturers, and because pharmacies may not always proactively reach out, it is possible for patients to remain unaware of a recall for weeks or months.

The Specific Recalls What Happened and Why

Prazosin Recall (2025) : Teva Pharmaceuticals announced in October 2025 that it was recalling more than 580,000 prazosin capsules due to elevated nitrosamine levels. Nitrosamines are impurities that can form during the manufacturing process when certain chemical reactions occur.

The FDA considers nitrosamines to be probable human carcinogens, meaning long-term exposure at sufficient levels could increase cancer risk. Prazosin is prescribed to approximately 510,000 patients in the U.S., primarily for hypertension, though it is also used off-label for conditions like post-traumatic stress disorder (PTSD)-related nightmares.

The recall covered 1 mg, 2 mg, and 5 mg capsules distributed by Teva, as well as 5 mg capsules distributed by Amerisource Health. Patients who had filled prescriptions from affected lots were advised to consult their healthcare provider about alternative treatments.

Enalapril Maleate Recall (2024) : Unique Pharmaceutical Laboratories recalled 675 bottles of 20 mg Enalapril Maleate Tablets after failed impurity tests. The FDA classified this as a Class II recall, meaning that while the defect could cause temporary or medically reversible health problems, the probability of serious adverse health consequences was remote.

Enalapril is an ACE inhibitor commonly prescribed for hypertension and heart failure. The specific impurity detected was not identified in the available reference content, but the recall serves as a reminder that even well-established generic drugs can have quality control lapses.

Bisoprolol/HCTZ (Ziac) Recall : Glenmark Pharmaceuticals voluntarily recalled more than 11,100 bottles of bisoprolol fumarate and hydrochlorothiazide tablets, sold under the brand name Ziac. Testing of reserve samples revealed possible contamination, prompting the recall.

Bisoprolol is a beta-blocker, and hydrochlorothiazide is a diuretic; the combination is used to treat hypertension. The specific contaminant was not detailed in available sources, but contamination can include microbial growth, chemical impurities, or physical defects such as improper dissolution.

Spironolactone Recall : The FDA recalled certain bottles of spironolactone tablets after finding possible aluminum contamination. Spironolactone is a potassium-sparing diuretic used to treat hypertension, heart failure, and other conditions.

Aluminum contamination in pharmaceutical products is concerning because aluminum can accumulate in the body over time, potentially affecting bone health and neurological function. However, the risk from short-term use of contaminated tablets is considered low.

Metoprolol Succinate ER Issues : The FDA warned that certain lots of Metoprolol Succinate ER (extended-release) tablets were not dissolving properly. This is a dissolution defect, meaning the tablet may not release the medication at the intended rate.

For extended-release formulations, improper dissolution can result in either too much drug being released at once (causing a dangerous drop in blood pressure) or too little being released (causing inadequate blood pressure control). More than 112,000 bottles were affected.

Products Labeled as "Green" Containing Tadalafil : In August 2025, FDA testing detected undeclared tadalafil in products labeled as "Green." Tadalafil is a prescription drug for erectile dysfunction that belongs to the class of phosphodiesterase-5 (PDE-5) inhibitors. The presence of an undeclared active ingredient is particularly dangerous because patients may have contraindications—for example, those taking nitrates for heart conditions can experience a life-threatening drop in blood pressure if they also take tadalafil.

Why Recalls Affect Generic Drugs More Frequently

The reference content suggests that older generic drugs may face higher safety risks. This observation aligns with broader industry trends: generic drugs are produced by multiple manufacturers, often in facilities with varying quality standards.

The profit margins on generics are lower than on brand-name drugs, which can pressure manufacturers to cut costs in areas like raw material sourcing, equipment maintenance, and quality control. Additionally, some generic drugs are produced at facilities that the FDA has not inspected recently.

The FDA inspects domestic and foreign manufacturing sites, but the agency's resources are limited. Facilities that produce drugs for both the U.S.

and other markets may have different levels of oversight depending on the destination country's regulatory framework. Another factor is that older generic drugs may use manufacturing processes that were developed decades ago.

As scientific understanding of impurity formation improves, new risks are identified in drugs that have been on the market for years. The nitrosamine issue is a prime example: the risk was not widely recognized until 2018, when recalls of ARBs like valsartan began.

Since then, the FDA has required manufacturers to test for nitrosamines across a broader range of drug classes, leading to additional recalls.

Common Questions and Misconceptions

"If my medication is recalled, should I stop taking it immediately?"

No. Stopping blood pressure medication abruptly can cause a dangerous spike in blood pressure, increasing the risk of heart attack or stroke.

The recall announcement may specify that patients should not stop taking the medication but should contact their healthcare provider for guidance. In most recalls, the contamination risk is low with short-term exposure, while the risk of uncontrolled hypertension is immediate and serious.

"Does a recall mean the drug is dangerous for everyone who takes it?"

Not necessarily. Recalls are typically issued for specific lots, not the entire drug product.

If a patient has a bottle from an affected lot, the contamination level may still be below the threshold that causes harm, especially with short-term use. The recall is a precautionary measure to remove potentially contaminated products from the market.

The FDA and manufacturers err on the side of caution, which is why some recalls involve relatively small quantities or low-level contamination.

"Are brand-name drugs safer than generics?"

No evidence in the reference content supports this claim. Recalls have affected both brand-name drugs like Pfizer's Accuretic and generic versions.

The manufacturing standards for brand-name and generic drugs are the same under FDA regulations. However, brand-name manufacturers often have more resources for quality control and may produce drugs in facilities with a longer track record of inspection compliance.

The key factor is the individual manufacturer's quality management system, not whether the drug is branded or generic.

"If I've been taking a recalled drug for years, does that mean I've been exposed to contaminants for a long time?"

Possibly, but the risk depends on the specific contaminant and the level of exposure. For nitrosamines, the risk is cumulative over a lifetime.

The FDA has established acceptable intake limits for nitrosamines in medications, meaning that even if a medication contains trace levels, the risk increase is small compared to other sources of nitrosamine exposure in food and the environment. Most recalls involve medications that have been on the market for a short period before the contamination was detected, so long-term exposure is less likely.

"Will I get a refund or compensation for a recalled medication?"

Patients who have purchased a recalled medication may be eligible for a refund from the pharmacy or the manufacturer. However, compensation for potential health effects is rare unless a patient can prove that the contaminated medication directly caused a specific injury.

The recall process is focused on public health, not financial restitution. Patients should keep their medication bottles and receipts in case a refund or medical monitoring program is offered.

What to Watch For (or Next Steps)

For Patients Currently Taking Blood Pressure Medication

First, do not panic. Most recalls involve low-level contamination that poses minimal risk with short-term use.

The immediate priority is to verify whether your medication is affected. Check the bottle or packaging for the lot number, manufacturer name, and expiration date, then compare this information against the FDA's recall list.

The FDA maintains a searchable database of all drug recalls on its website, updated in real time. If your medication is on the recall list, contact your pharmacy to confirm the status and ask if a replacement lot is available.

Your pharmacy should be able to check the lot number against the recall announcement. If you have unused medication from an affected lot, do not throw it away yet—some pharmacies may require you to return it for proper disposal or for evidence if a refund is offered.

Next, contact your healthcare provider. Your doctor can prescribe an alternative medication from the same drug class or a different class that is not affected by the recall.

In many cases, there are multiple options for controlling blood pressure, including ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, and diuretics. Your provider will consider your medical history, current blood pressure readings, and any side effects you may have experienced.

Do not attempt to switch medications on your own. Blood pressure medications work differently in the body, and abrupt changes can cause blood pressure fluctuations.

Your doctor needs to determine the appropriate dosage and monitor your response to the new medication.

For Patients Not Currently on a Recalled Medication

Even if your specific drug is not affected, stay informed about recalls affecting your medication class. Subscribe to FDA email alerts or bookmark the FDA recall page.

When you fill a prescription, ask the pharmacist whether there have been any recent recalls for that drug. Pharmacists have access to real-time recall information and can alert you to any issues.

Consider signing up for medication safety alerts from independent organizations. The FDA provides a free subscription service for safety alerts, including recalls, market withdrawals, and safety warnings.

This can be set up by drug class or specific product.

For Healthcare Providers and Pharmacists

Healthcare providers should review their patient lists for those prescribed affected medications and proactively contact them. The recall of prazosin, for example, affected approximately 510,000 patients—a large enough population to warrant systematic outreach.

Providers should prepare alternative treatment plans in advance so that patients can transition smoothly without gaps in therapy. Pharmacists play a critical role in the recall process.

When a patient brings in a prescription bottle from an affected lot, the pharmacist can verify the recall status, provide a replacement if available, and document the return for reporting to the manufacturer. Pharmacies should also have procedures in place to notify patients who may have filled prescriptions from affected lots but have not yet been contacted.

What the FDA and Manufacturers Should Do

The FDA should continue to strengthen its inspection and testing programs for both domestic and foreign manufacturing facilities. The recurrence of nitrosamine contamination across multiple drug classes suggests that the root cause—manufacturing process design—has not been fully addressed.

The FDA could require manufacturers to submit detailed impurity risk assessments for all high-risk drug products before they are approved for market. Manufacturers should invest in more rigorous quality control testing, particularly for drugs that are known to be at risk for impurity formation.

The recall of 580,000 prazosin capsules by Teva indicates that even large, established pharmaceutical companies can miss contamination during production. Implementing real-time impurity monitoring during manufacturing, rather than relying on end-product testing, could catch problems earlier and reduce the number of affected batches.

Frequently Asked Questions

How do I know if my blood pressure medication has been recalled?

Check the label on your prescription bottle for the lot number, manufacturer name, and expiration date. Compare this information against the FDA's recall list, which is available on the FDA website and updated regularly.

You can also ask your pharmacist to verify whether your specific lot is affected. Some pharmacies have automatic notification systems that alert patients when a recall is announced.

Should I stop taking my medication if I suspect it might be recalled?

No. Never stop taking prescribed blood pressure medication without consulting your healthcare provider first.

Stopping abruptly can cause a dangerous increase in blood pressure, which carries immediate risks of heart attack, stroke, or other complications. Contact your doctor or pharmacist to confirm whether your medication is affected and to discuss alternative options.

What should I do if my medication is recalled?

First, contact your pharmacy to confirm the recall and ask if a replacement lot is available. Then, contact your healthcare provider to get a new prescription for an alternative medication.

Keep your original bottle in case the manufacturer or pharmacy requests a return. Do not discard the medication until you have confirmed the proper disposal procedure with your pharmacy or local waste authority.

Are there any symptoms I should watch for if I've been taking a recalled medication?

For most recalls involving low-level contamination, there are no immediate symptoms. Nitrosamine exposure is associated with long-term cancer risk, not acute illness.

If your medication was found to contain undeclared ingredients (such as tadalafil), you may experience side effects like headache, flushing, dizziness, or changes in vision. If you have chest pain, difficulty breathing, or severe dizziness, seek medical attention immediately.

Will I be notified personally if my medication is recalled?

Not always. Manufacturers are required to notify distributors and retailers, but they may not have direct contact information for individual patients.

Pharmacies may post notices or contact patients who filled prescriptions from affected lots, but this is not guaranteed. The best way to stay informed is to check the FDA recall list periodically and to sign up for FDA safety alerts.

Reference Notes

Information in this article is based on publicly available sources. Some details may change over time.

Verify with official sources before acting.